ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 129 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,997 | -29.5% | 13,262 | 0.0% | 0.00% | – |
| Q2 2023 | $18,434 | -10.3% | 13,262 | +2.6% | 0.00% | – |
| Q1 2023 | $20,551 | -74.5% | 12,925 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $80,523 | -7.4% | 12,925 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $87,000 | +6.1% | 12,925 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $82,000 | +36.7% | 12,925 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $60,000 | -7.7% | 12,925 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $65,000 | -58.6% | 12,925 | -0.8% | 0.00% | -50.0% |
| Q3 2021 | $157,000 | -26.3% | 13,025 | +29.6% | 0.00% | -33.3% |
| Q2 2021 | $213,000 | -23.9% | 10,050 | +0.8% | 0.00% | -50.0% |
| Q1 2021 | $280,000 | +4.1% | 9,975 | -3.6% | 0.01% | 0.0% |
| Q4 2020 | $269,000 | -33.3% | 10,350 | -4.6% | 0.01% | -40.0% |
| Q3 2020 | $403,000 | -34.6% | 10,850 | -9.6% | 0.01% | -37.5% |
| Q2 2020 | $616,000 | +170.2% | 12,000 | +65.6% | 0.02% | +100.0% |
| Q1 2020 | $228,000 | +12.3% | 7,247 | +113.0% | 0.01% | +60.0% |
| Q4 2019 | $203,000 | – | 3,402 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 3,791,300 | $3,715,474 | 4.82% |
| Two Seas Capital LP | 7,672,170 | $7,518,727 | 1.51% |
| Parkman Healthcare Partners LLC | 1,997,071 | $1,957,130 | 0.36% |
| Monaco Asset Management SAM | 1,171,779 | $1,148,343 | 0.34% |
| TANG CAPITAL MANAGEMENT LLC | 1,850,000 | $1,813,000 | 0.26% |
| Ikarian Capital, LLC | 1,737,636 | $1,702,883 | 0.20% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 3,189,517 | $3,125,727 | 0.12% |
| GSA CAPITAL PARTNERS LLP | 1,116,655 | $1,094 | 0.09% |
| XTX Topco Ltd | 519,129 | $508,746 | 0.09% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 60,000 | $58,800 | 0.08% |